Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bernstein-Molho Rinat, Sella Tal, Delucchi Virginia, Coussy Florence, Kim Hee Jeong, Linn Sabine, Di Meglio Antonio, Pogoda Katarzyna, Kwong Ava, Agostinetto Elisa, Bajpai Jyoti, Van Herck Yannick, Ferrari Alberta, Balmana Judith, Moore Halle C F, Peccatori Fedro A, Partridge Ann H, Winocur Melina, Renaud Tiphaine, Rousset-Jablonski Christine, Lee Jeong Eon, Toss Angela, Paluch-Shimon Shani, Wong Stephanie M, Matikas Alexios, Villarreal-Garza Cynthia, Vernieri Claudio, Lee Minna, Guven Deniz Can, Cui Wanda, Ruddy Kathryn J, Dieci Maria Vittoria, Fruscio Robert, De Marchis Laura, Kemp Zoe, Meireles Pedro A, Razeti Maria Grazia, Diz Maria Del Pilar, Hwang Shelley E, Puglisi Fabio, Clatot Florian, Yerushalmi Rinat, Cichowska-Cwalinska Natalia, Chirco Alessandra, De Angelis Carmine, Blondeaux Eva, Lambertini Matteo
Аннотация
METHODS: The BRCA BCY Collaboration (NCT03673306) is an international, multicenter, retrospective cohort study of BRCA carriers diagnosed with stage I-III BC at age ≤ 40 years, between 2000 and 2020. Disease-free survival (DFS) and overall survival (OS) were assessed among patients with HER2-negative disease treated with anthracycline-taxane, anthracycline-no-taxane, or non-anthracycline (neo)adjuvant chemotherapy. The association of platinum use with outcomes was evaluated in triple-negative breast cancer (TNBC).
RESULTS: Among 4200 young BRCA carriers from 109 centres who received (neo)adjuvant chemotherapy for HER2-negative BC, 58.7% had TNBC. Median follow-up was 8.1 years (IQR, 4.7-12.6 years). Anthracycline-taxane, anthracycline-no-taxane, and non-anthracycline regimens were used in 74.4%, 19.3%, and 6.3% of patients, respectively. Platinum agents were administered in 19.8% of TNBC cases. After multivariable adjustment, no significant differences in DFS or OS were observed between anthracycline-no-taxane and anthracycline-taxane regimens (DFS adjusted hazard ratio [aHR] 0.88, 95% CI 0.73-1.05; OS aHR 1.20, 95% CI 0.87-1.67) or non-anthracycline regimens (DFS aHR 1.07, 95% CI 0.82-1.38; OS aHR 1.16, 95% CI 0.68-2.0). In TNBC, platinum use was not associated with improved outcomes.
CONCLUSIONS: In young BRCA carriers with HER2-negative early BC, no statistically significant differences in survival outcomes were detected across different chemotherapy regimens. Our findings may inform future prospective studies evaluating chemotherapy de-escalation strategies in this genetically defined population.